P-Cymene

P-Cymene

SCHEMBL3579869

Cc1ccc(C(C)C)cc1.Cc1ccc(S(=O)(=O)N[C@H](c2ccccc2)[C@H](N)c2ccccc2)cc1.[Ru]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
NPSR1 Q6W5P4 3/20 0.50
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
HTT P42858 2/20 0.44
CNR2 P34972 1/20 0.44
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
GBA1 P04062 1/20 0.43
HPN P05981 2/20 0.42
PLAU P00749 1/20 0.42
CA2 P00918 5/20 0.42
CA1 P00915 3/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Cymene SCHEMBL2240125 1.00 ALDH1A1 (0.50) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL7527837 0.97 NPSR1 (0.47) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL6743208 0.97 NPSR1 (0.47) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL3341178 0.96 NPSR1 (0.49) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL7517875 0.94 ALDH1A1 (0.46) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Cymene SCHEMBL6740633 0.94 ALDH1A1 (0.46) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
Benzene SCHEMBL3854289 0.93 ALDH1A1 (0.52) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL28382647 0.93 ALDH1A1 (0.52) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
SCHEMBL3342411 0.93 ALDH1A1 (0.52) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1
P-Xylene SCHEMBL5421492 0.93 ALDH1A1 (0.52) ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217031-B2 Heteroaryl derivatives NIPPON SHINYAKU CO., LTD. (JP) 2012-07-10 US disclosed
US-20100048537-A1 HETEROARYL DERIVATIVES NIPPON SHINYAKU CO., LTD. (JP) 2010-02-25 US disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-7332622-B2 Process for preparing optically active nitro compounds and cyano compounds KANTO KAGUKU KABUSHIKI KAISHA (JP) 2008-02-19 US disclosed
US-7268250-B2 Process for producing optically active compound KANTO KAGAKU KABUSHIKI KAISHA (JP) 2007-09-11 US disclosed
EP-1308435-B1 Process for producing optically active amino alcohols KANTO KAGAKU (JP) 2005-12-28 EP disclosed
US-20050101787-A1 Process for preparing optically active nitro compounds and cyano compounds KANTO KAGAKU KABUSHIKI KAISHA (JP) 2005-05-12 US disclosed
EP-1512678-A1 Process for preparing optically active nitro compounds and cyano compounds Kanto Kagaku Kabushiki Kaisha (JP) 2005-03-09 EP disclosed
US-20040176616-A1 Process for producing optically active compound KANTO KAGAKU KABUSHIKI KAISHA 2004-09-09 US disclosed
US-6686505-B2 HYDROGENATION OF NITRO KETONE OR CYANO KETONE IN PRESENCE OF TRANSITION METAL COMPOUND CATALYST; AMINATION KANTO KAGUKU KABUSHIKI KAISHA (JP) 2004-02-03 US disclosed
US-20030171592-A1 Process for producing optically active amino alcohols and intermediates therefore KANTO KAGAKU KABUSHIKI KAISHA (JP) 2003-09-11 US disclosed
EP-1308435-A2 Process for producing optically active amino alcohols Kanto Kagaku Kabushiki Kaisha (JP) 2003-05-07 EP disclosed
US-6495701-B1 THE PRESENT INVENTION IS DIRECTED TO PROCESSES FOR THE PREPARATION OF A COMPOUND USEFUL FOR TREATING DIABETES, OBESITY, HYPERLIPIDEMIA AND THE LIKE, ASAHI KASEI KABUSHIKI KAISHA (JP) 2002-12-17 US disclosed
EP-1174426-A1 METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES Asahi Kasei Kabushiki Kaisha (JP) 2002-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171592-A1 Process for producing optically active amino alcohols and intermediates therefore ADH1A, NOS1, ADH5 ALDH1A1 151/4885NPSR1 1710/4885SLC1A3 233/4885
US-20040176616-A1 Process for producing optically active compound OSTC, NPEPPS, PPOX ALDH1A1 3566/4885NPSR1 3017/4885SLC1A3 4283/4885
US-20050101787-A1 Process for preparing optically active nitro compounds and cyano compounds NOS1, NOS2, NOX1 ALDH1A1 1008/4885NPSR1 2609/4885SLC1A3 1768/4885
US-20100048537-A1 HETEROARYL DERIVATIVES OPRD1, OPRM1, OPRK1 ALDH1A1 66/4885NPSR1 13/4885SLC1A3 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.